Pediatric biopharmaceutics: translating gastrointestinal characteristics into improved predictive absorption tools. KU Leuven
Until recently, pharmaceutical companies have never been encouraged to perform clinical studies in the pediatric population; as a result, off-label use of drugs in children is still common. Regulatory authorities have recognized this problem and have introduced incentives and requirements for the pharmaceutical industry to include pediatric studies in their development programs. An efficient drug development process is guided by reliable ...